The DOI matches its Crossref record; 44 of the 46 references it cites were found in a registry or an index.
A Modified γ-Retrovirus Vector for X-Linked Severe Combined Immunodeficiency
Open accessAbstract
BACKGROUND: In previous clinical trials involving children with X-linked severe combined immunodeficiency (SCID-X1), a Moloney murine leukemia virus-based γ-retrovirus vector expressing interleukin-2 receptor γ-chain (γc) complementary DNA successfully restored immunity in most patients but resulted in vector-induced leukemia through enhancer-mediated mutagenesis in 25% of patients. We assessed the efficacy and safety of a self-inactivating retrovirus for the treatment of SCID-X1. METHODS: We enrolled nine boys with SCID-X1 in parallel trials in Europe and the United States to evaluate treatment with a self-inactivating (SIN) γ-retrovirus vector containing deletions in viral enhancer sequences expressing γc (SIN-γc). RESULTS: All patients received bone marrow-derived CD34+ cells transduced with the SIN-γc vector, without preparative conditioning. After 12.1 to 38.7 months of follow-up, eight of the nine children were still alive. One patient died from an overwhelming adenoviral infection before reconstitution with genetically modified T cells. Of the remaining eight patients, seven had recovery of peripheral-blood T cells that were functional and led to resolution of infections. The patients remained healthy thereafter. The kinetics of CD3+ T-cell recovery was not significantly different from that observed in previous trials. Assessment of insertion sites in peripheral blood from patients in the current trial as compared with those in previous trials revealed significantly less clustering of insertion sites within LMO2, MECOM, and other lymphoid proto-oncogenes in our patients. CONCLUSIONS: This modified γ-retrovirus vector was found to retain efficacy in the treatment of SCID-X1. The long-term effect of this therapy on leukemogenesis remains unknown. (Funded by the National Institutes of Health and others; ClinicalTrials.gov numbers, NCT01410019, NCT01175239, and NCT01129544.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Initial sequencing and analysis of the human genome
International Human Genome Sequencing Consortium, Whitehead Institute for Biomedical Research, C. F. G. R., Lander, E. S., Linton, L. M., Birren, B., Nusbaum, C., Zody, M. C., Baldwin, J., Devon, K., Dewar, K., et al. (2001) · Nature · doi:10.1038/35057062 · Cited by 24,216
Bioconductor: open software development for computational biology and bioinformatics
Gentleman, R. C., Carey, V. J., Bates, D. M., Bolstad, B., Dettling, M., Dudoit, S., Ellis, B., Gautier, L., Ge, Y., Gentry, J., et al. (2004) · Genome biology · doi:10.1186/gb-2004-5-10-r80 · Cited by 12,082
Vogelstein, B., Papadopoulos, N., Velculescu, V. E., Zhou, S., Diaz, L. A., & Kinzler, K. W. (2013) · Science · doi:10.1126/science.1235122 · Cited by 7,863
LMO2 -Associated Clonal T Cell Proliferation in Two Patients after Gene Therapy for SCID-X1
Hacein-Bey-Abina, S., Von Kalle, C., Schmidt, M., McCormack, M. P., Wulffraat, N., Leboulch, P., Lim, A., Osborne, C. S., Pawliuk, R., Morillon, E., et al. (2003) · Science · doi:10.1126/science.1088547 · Cited by 3,587
Self-citationGene Therapy of Human Severe Combined Immunodeficiency (SCID)-X1 Disease
Cavazzana, M., Hacein‐Bey‐Abina, S., Basile, G. D. S., Gross, F., Yvon, E. S., Nusbaum, P., Selz, F., Hue, C., Dogniaux, S., Casanova, J., et al. (2000) · Science · doi:10.1126/science.288.5466.669 · Cited by 2,685
Self-citationAkaike's Information Criterion in Generalized Estimating Equations
Pan, W. (2001) · Biometrics · doi:10.1111/j.0006-341x.2001.00120.x · Cited by 2,545
Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1
Hacein-Bey-Abina, S., Garrigue, A., Wang, G. P., Soulier, J., Lim, A., Morillon, E., Clappier, E., Caccavelli, L., Delabesse, E., Beldjord, K., et al. (2008) · Journal of Clinical Investigation · doi:10.1172/jci35700 · Cited by 1,854
Self-citationGeneralized Estimating Equations
Hardin, J. W., & Hilbe, J. M. (2002) · doi:10.1201/9781420035285 · Cited by 1,766
Noguchi, M. (1993) · Cell · doi:10.1016/0092-8674(93)90167-o · Cited by 1,338
Howe, S. J., Mansour, M. R., Schwarzwaelder, K., Bartholomae, C., Hubank, M., Kempski, H., Brugman, M. H., Pike-Overzet, K., Chatters, S. J., de Ridder, D., et al. (2008) · Journal of Clinical Investigation · doi:10.1172/jci35798 · Cited by 1,286
Self-citation
Research works printed but not linked: 2
- Gaspar HB, 2011, Sci Transl Med, 3, 97ra79
- Coffin JM, Hughes SH, Varmus HE. Retroviruses. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press, 1997.
Cited by
Sorted by citations
Items 101–200 of 411
Novel Genome-Editing Tools to Model and Correct Primary Immunodeficiencies
de Bruin, L. M. O., Volpi, S., & Musunuru, K. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00250 · Cited by 44
Regulatory Consideration for the Nonclinical Safety Assessment of Gene Therapies
Moffit, J. S., Blanset, D. L., Lynch, J. L., MacLachlan, T. K., Meyer, K. E., Ponce, R. A., & Whiteley, L. O. (2022) · Human Gene Therapy · doi:10.1089/hum.2022.090 · Cited by 39
Retroviral Vectors for Cancer Gene Therapy
Schambach, A., & Morgan, M. A. (2016) · Recent results in cancer research/Recent Results in Cancer Research · doi:10.1007/978-3-319-42934-2_2 · Cited by 39
Self-citationLong term outcomes of severe combined immunodeficiency: therapy implications
Heimall, J. R., & Cowan, M. J. (2017) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2017.1381558 · Cited by 42
Therapeutic gene editing in haematological disorders with CRISPR /Cas9
Jensen, T. I., Axelgaard, E., & Bak, R. O. (2019) · British Journal of Haematology · doi:10.1111/bjh.15851 · Cited by 40
Gene therapy for blood diseases
Kohn, D. B. (2019) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2018.11.016 · Cited by 39
Self-citationLarge-scale production of lentiviral vector in a closed system hollow fiber bioreactor
Sheu, J. I., Beltzer, J., Fury, B., Wilczek, K., Tobin, S., Falconer, D., Nolta, J. A., & Bauer, G. (2015) · Molecular Therapy — Methods & Clinical Development · doi:10.1038/mtm.2015.20 · Cited by 39
Retroviral gene therapy in Germany with a view on previous experience and future perspectives
Morgan, M. A., Galla, M., Grez, M., Fehse, B., & Schambach, A. (2021) · Gene Therapy · doi:10.1038/s41434-021-00237-x · Cited by 39
Self-citationStem cell manipulation, gene therapy and the risk of cancer stem cell emergence
Clément, F., Grockowiak, É., Zylbersztejn, F., Fossard, G., Gobert, S., & Maguer‐Satta, V. (2017) · Stem Cell Investigation · doi:10.21037/sci.2017.07.03 · Cited by 39
Genetic therapies for sickle cell disease
Esrick, E. B., & Bauer, D. E. (2018) · Seminars in Hematology · doi:10.1053/j.seminhematol.2018.04.014 · Cited by 39
Daniel-Moreno, A., Lamsfus‐Calle, A., Raju, J., Antony, J. S., Handgretinger, R., & Mezger, M. (2019) · Bone Marrow Transplantation · doi:10.1038/s41409-019-0510-8 · Cited by 40
Gene therapy and genome editing for primary immunodeficiency diseases
Zhang, Z., Thrasher, A. J., & Zhang, F. (2019) · Genes & Diseases · doi:10.1016/j.gendis.2019.07.007 · Cited by 38
Self-citationThe retroviral vector family: something for everyone
Elsner, C., & Bohne, J. (2017) · Virus Genes · doi:10.1007/s11262-017-1489-0 · Cited by 36
Brendel, C., Río, P., & Verhoeyen, E. (2019) · Biochemical Pharmacology · doi:10.1016/j.bcp.2019.113711 · Cited by 39
Lentiviral Hematopoietic Stem Cell Gene Therapy Corrects Murine Pompe Disease
Stok, M., de Boer, H., Huston, M. W., Jacobs, E. H., Roovers, O., Visser, T. P., Jahr, H., Duncker, D. J., van Deel, E. D., Reuser, A. J. J., et al. (2020) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2020.04.023 · Cited by 37
Multiplex HDR for disease and correction modeling of SCID by CRISPR genome editing in human HSPCs
Iancu, O., Allen, D. G., Knop, O., Zehavi, Y., Breier, D., Arbiv, A., Lev, A., Lee, Y. N., Beider, K., Nagler, A., et al. (2022) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2022.12.006 · Cited by 37
UM171 Enhances Lentiviral Gene Transfer and Recovery of Primitive Human Hematopoietic Cells
Ngom, M., Imren, S., Maetzig, T., Adair, J. E., Knapp, D. J. H. F., Chagraoui, J., Fares, I., Bordeleau, M.-È., Sauvageau, G., Leboulch, P., et al. (2018) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2018.06.009 · Cited by 37
Can preclinical drug development help to predict adverse events in clinical trials?
Chi, L. H., Burrows, A. D., & Anderson, R. L. (2021) · Drug Discovery Today · doi:10.1016/j.drudis.2021.08.010 · Cited by 34
Zhang, K., Wan, P., Wang, L., Wang, Z., Tan, F., Li, J., Ma, X., Cen, J., Yuan, X., Liu, Y., et al. (2024) · Cell stem cell · doi:10.1016/j.stem.2024.04.022 · Cited by 36
Clarke, E., Connell, A. J., Six, E. M., Kadry, N. A., Abbas, A. A., Hwang, Y., Everett, J. K., Hofstaedter, C. E., Marsh, R. A., Armant, M. A., et al. (2018) · Genome Medicine · doi:10.1186/s13073-018-0580-z · Cited by 33
Self-citationDettmer‐Monaco, V., Bloom, K. M., Groß, M., Weißert, K., Aichele, P., Ehl, S. R., & Cathomen, T. (2019) · Human Gene Therapy · doi:10.1089/hum.2019.025 · Cited by 33
Cornetta, K. G., Lin, T., Pellin, D., & Kohn, D. B. (2022) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2022.11.009 · Cited by 35
Self-citationHogan, D. J., Zhu, J., Diago, O. R., Gammon, D., Haghighi, A., Lu, G., Das, A., Gruber, H. E., Jolly, D. J., & Ostertag, D. G. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0619 · Cited by 33
Tersteeg, C., Verhenne, S., Roose, E., Schelpe, A., Deckmyn, H., Meyer, S. F. D., & Vanhoorelbeke, K. (2015) · Expert Review of Hematology · doi:10.1586/17474086.2016.1122515 · Cited by 32
Cooper, A. R., Lill, G. R., Shaw, K. L., Carbonaro-Sarracino, D. A., Davila, A., Sokolic, R. A., Candotti, F., Pellegrini, M. A., & Kohn, D. B. (2017) · Blood · doi:10.1182/blood-2016-12-756734 · Cited by 31
Self-citationBrault, J., Liu, T., Liu, S., Lawson, A., Choi, U., Kozhushko, N., Bzhilyanskaya, V., Pavel-Dinu, M., Meis, R. J., Eckhaus, M., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1067417 · Cited by 33
Self-citationTreatment of primary immunodeficiency with allogeneic transplant and gene therapy
Pai, S. (2019) · Hematology · doi:10.1182/hematology.2019000052 · Cited by 31
Self-citationGene therapy in pediatrics – Clinical studies and approved drugs (as of 2023)
Gol, T. M., Zahedipour, F., Trosien, P., Ureña-Bailén, G., Kim, M., Antony, J. S., & Mezger, M. (2024) · Life Sciences · doi:10.1016/j.lfs.2024.122685 · Cited by 30
Recent challenges and advances in genetically-engineered cell therapy
Yong, S., Chung, J. Y., Song, Y., & Kim, Y. (2017) · Journal of Pharmaceutical Investigation · doi:10.1007/s40005-017-0381-1 · Cited by 30
In vivo engineering of lymphocytes after systemic exosome-associated AAV delivery
Breuer, C. B., Hanlon, K. S., Natasan, J.-S., Volak, A., Meliani, A., Mingozzi, F., Kleinstiver, B. P., Moon, J. J., & Maguire, C. A. (2020) · Scientific Reports · doi:10.1038/s41598-020-61518-w · Cited by 30
Torres‐Torronteras, J., Cabrera-Pérez, R., Barba, I., Costa, C., de Luna, N., Andreu, A. L., Barquinero, J., Hirano, M., Cámara, Y., & Martí, R. (2016) · Human Gene Therapy · doi:10.1089/hum.2015.160 · Cited by 31
Gene Therapy for Pompe Disease: The Time is now
Colella, P., & Mingozzi, F. (2019) · Human Gene Therapy · doi:10.1089/hum.2019.109 · Cited by 31
Humbert, O., Chan, F., Rajawat, Y. S., Torgerson, T. R., Burtner, C. R., Hubbard, N., Humphrys, D. R., Norgaard, Z. K., O’Donnell, P., Adair, J. E., et al. (2018) · Blood Advances · doi:10.1182/bloodadvances.2018016451 · Cited by 29
Novel extragenic genomic safe harbors for precise therapeutic T cell engineering
Odak, A., Yuan, H., Feucht, J., Cantu, A., Mansilla‐Soto, J., Kogel, F., Eyquem, J., Everett, J. K., Bushman, F. D., Leslie, C. S., et al. (2023) · Blood · doi:10.1182/blood.2022018924 · Cited by 28
Self-citationInnovative Treatments for Lysosomal Diseases
Cox, T. M. (2015) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2015.01.001 · Cited by 28
A primer to gene therapy: Progress, prospects, and problems
Zittersteijn, H. A., Gonçalves, M. A. F. V., & Hoeben, R. C. (2020) · Journal of Inherited Metabolic Disease · doi:10.1002/jimd.12270 · Cited by 28
Sites of retroviral DNA integration: From basic research to clinical applications
Serrao, E., & Engelman, A. (2015) · Critical Reviews in Biochemistry and Molecular Biology · doi:10.3109/10409238.2015.1102859 · Cited by 32
Boehme, P., Zhang, W., Solanki, M., Ehrke‐Schulz, E., & Ehrhardt, A. (2016) · Molecular Therapy — Nucleic Acids · doi:10.1038/mtna.2016.44 · Cited by 27
Debnath, S., Jaako, P., Siva, K., Rothe, M., Chen, J., Dahl, M., Gaspar, H. B., Flygare, J., Schambach, A., & Karlsson, S. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.04.002 · Cited by 27
Self-citationAdvances in the gene therapy of monogenic blood cell diseases
Bueren, J. A., Bustamante, O. Q., Almarza, E., Navarro, S., Rı́o, P., Segovia, J. C., & Güenechea, G. (2019) · Clinical Genetics · doi:10.1111/cge.13593 · Cited by 28
Hematopoietic stem cell gene therapy: The optimal use of lentivirus and gene editing approaches
Lamsfus‐Calle, A., Daniel-Moreno, A., Ureña-Bailén, G., Raju, J., Antony, J. S., Handgretinger, R., & Mezger, M. (2019) · Blood Reviews · doi:10.1016/j.blre.2019.100641 · Cited by 29
Gene therapy for X-linked severe combined immunodeficiency: Historical outcomes and current status
Pai, S., & Thrasher, A. J. (2020) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2020.05.055 · Cited by 27
Self-citationDevelopment and clinical translation of ex vivo gene therapy
Wu, X., He, X., Liu, F., Jiang, X., Wang, P., Zhang, J., & Jiang, J. (2022) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2022.06.015 · Cited by 28
In-Vivo Gene Therapy with Foamy Virus Vectors
Rajawat, Y. S., Humbert, O., & Kiem, H. (2019) · Viruses · doi:10.3390/v11121091 · Cited by 27
Gene therapy for primary immunodeficiencies
Fox, T. A., & Booth, C. (2020) · British Journal of Haematology · doi:10.1111/bjh.17269 · Cited by 27
Recent advances in understanding the pathophysiology of primary T cell immunodeficiencies
Fischer, A. (2015) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2015.04.002 · Cited by 25
Self-citationGenetic Engineering and Manufacturing of Hematopoietic Stem Cells
Wang, X., & Rivière, I. (2017) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2017.03.003 · Cited by 25
Advances in basic and clinical immunology in 2014
Chinen, J., Notarangelo, L. D., & Shearer, W. T. (2015) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2015.02.037 · Cited by 24
Self-citationAdvances in gene therapy for inborn errors of immunity
de Bruin, L. M. O., Lankester, A. C., & Staal, F. J. T. (2023) · Current Opinion in Allergy and Clinical Immunology · doi:10.1097/aci.0000000000000952 · Cited by 24
Engineering Next-Generation BET-Independent MLV Vectors for Safer Gene Therapy
Ashkar, S. E., Looveren, D. V., Schenk, F., Vranckx, L. S., Demeulemeester, J., Rijck, J. D., Debyser, Z., Modlich, U., & Gijsbers, R. (2017) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2017.04.002 · Cited by 24
Update on Advances in Hematopoietic Cell Transplantation for Primary Immunodeficiency Disorders
Shamriz, O., & Chandrakasan, S. (2018) · Immunology and Allergy Clinics of North America · doi:10.1016/j.iac.2018.08.003 · Cited by 24
Hematopoietic Stem Cell Gene Therapy for Brain Metastases Using Myeloid Cell–Specific Gene Promoters
Andreou, T., Rippaus, N., Wronski, K., Williams, J. M., Taggart, D., Cherqui, S., Sunderland, A., Kartika, Y. D., Egnuni, T., Brownlie, R. J., et al. (2019) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djz181 · Cited by 24
Verhenne, S., Vandeputte, N., Pareyn, I., Izsvák, Z., Rottensteiner, H., Deckmyn, H., Meyer, S. F. D., & Vanhoorelbeke, K. (2017) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.116.308680 · Cited by 23
Recent advances in gene‐enhanced bone tissue engineering
Betz, V. M., Kochanek, S., Rammelt, S., Müller, P. E., Betz, O. B., & Messmer, C. (2018) · The Journal of Gene Medicine · doi:10.1002/jgm.3018 · Cited by 23
Steffin, D., Hsieh, E. M., & Rouce, R. H. (2019) · Advances in Pediatrics · doi:10.1016/j.yapd.2019.04.001 · Cited by 24
Reconstructing the immune system with lentiviral vectors
Olbrich, H., Slabik, C., & Stripecke, R. (2017) · Virus Genes · doi:10.1007/s11262-017-1495-2 · Cited by 22
Cruz, L. J., Rezaei, S., Grosveld, F. G., Philipsen, S., & Eich, C. (2022) · Frontiers in Genome Editing · doi:10.3389/fgeed.2022.1030285 · Cited by 23
T Cell Acute Lymphoblastic Leukemia as a Consequence of Thymus Autonomy
Ballesteros-Arias, L., da Silva, J. G., Paiva, R. A., Carbonetto, B., Faísca, P., & Martins, V. C. (2019) · The Journal of Immunology · doi:10.4049/jimmunol.1801373 · Cited by 24
Function and Safety of Lentivirus-Mediated Gene Transfer for CSF2RA -Deficiency
Hetzel, M., Suzuki, T., Hashtchin, A. R., Arumugam, P. I., Carey, B. C., Schwabbauer, M., Kuhn, A., Meyer, J., Schambach, A., van der Loo, J. C. M., et al. (2017) · Human Gene Therapy Methods · doi:10.1089/hgtb.2017.092 · Cited by 21
Self-citationNogalska, A., Eerdeng, J., Akre, S., Vergel-Rodriguez, M., Lee, Y., Bramlett, C. S., Chowdhury, A. Y., Wang, B., Cess, C. G., Finley, S. D., et al. (2024) · Cellular and Molecular Immunology · doi:10.1038/s41423-024-01225-y · Cited by 20
Urbinati, F., Wherley, J., Geiger, S., Fernandez, B. C., Kaufman, M. L., Cooper, A. R., Romero, Z. G., Marchioni, F., Reeves, L., Read, E. J., et al. (2017) · Cytotherapy · doi:10.1016/j.jcyt.2017.06.002 · Cited by 20
Self-citationGeneration of High-Titer Self-Inactivated γ-Retroviral Vector Producer Cells
Ghani, K., Boivin-Welch, M., Roy, S., Piaceski, A. D., Barbier, M. A., Pope, E., Germain, L., & Caruso, M. (2019) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2019.05.013 · Cited by 20
Advances in viral vector-based delivery systems for gene therapy: a comprehensive review
Singh, K., Jain, D., Sethi, P., Gupta, J. K., Dubey, A., Noman, A. A., lal, S., Sharma, P., & Abdallah, E. M. (2025) · 3 Biotech · doi:10.1007/s13205-025-04366-7 · Cited by 21
Asif, M., Khan, W. J., Aslam, S., Aslam, A., & Chowdhury, M. A. (2024) · Cureus · doi:10.7759/cureus.57869 · Cited by 19
Deng, H.-X., Wang, Y., Ding, Q.-R., Li, D., & Wei, Y.-Q. (2017) · Gene Therapy · doi:10.1038/gt.2017.62 · Cited by 19
Gene Therapy Cargoes Based on Viral Vector Delivery
Lundstrom, K. H. (2022) · Current Gene Therapy · doi:10.2174/1566523222666220921112753 · Cited by 19
Viral Vectors in Gene Replacement Therapy
Minskaia, E., Galieva, A., Egorov, A. D., Ivanov, R. A., & Karabelsky, A. V. (2023) · Biochemistry (Moscow) · doi:10.1134/s0006297923120179 · Cited by 19
Emerging trends in virus and virus-like particle gene therapy delivery to the brain
Mandalawatta, H. P. P., Rajendra, K. C., Fairfax, K. A., & Hewitt, A. W. (2024) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2024.102280 · Cited by 18
Viral Vectors, Engineered Cells and the CRISPR Revolution
DiCarlo, J. E., Deeconda, A., & Tsang, S. H. (2017) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-63904-8_1 · Cited by 19
T-cell receptor gene-modified cells: past promises, present methodologies and future challenges
Rego, R. T., Morris, E. C., & Lowdell, M. W. (2019) · Cytotherapy · doi:10.1016/j.jcyt.2018.12.002 · Cited by 23
Gene therapy for inborn errors of immunity
Wijeyesinghe, S., & Chinen, J. (2025) · Annals of Allergy Asthma & Immunology · doi:10.1016/j.anai.2025.02.026 · Cited by 17
Ochs, H. D., & Petroni, D. (2017) · American Journal of Medical Genetics Part A · doi:10.1002/ajmg.a.38480 · Cited by 17
Pais, G., Spinozzi, G., Cesana, D., Benedicenti, F., Albertini, A., Bernardo, M. E., Gentner, B., Montini, E., & Calabria, A. (2022) · Briefings in Bioinformatics · doi:10.1093/bib/bbac551 · Cited by 17
Integrating Vectors for Gene Therapy and Clonal Tracking of Engineered Hematopoiesis
Biasco, L., Rothe, M., Schott, J. W., & Schambach, A. (2017) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2017.06.009 · Cited by 17
Self-citationChimeric Antigen Receptor T Cells: Extending Translation from Liquid to Solid Tumors
Morgan, M. A., & Schambach, A. (2018) · Human Gene Therapy · doi:10.1089/hum.2017.251 · Cited by 18
Self-citationT cell gene therapy to treat immunodeficiency
Panchal, N., Ghosh, S., & Booth, C. (2020) · British Journal of Haematology · doi:10.1111/bjh.17070 · Cited by 18
Gene Therapy for Primary Immunodeficiency
Houghton, B. C., & Booth, C. (2020) · HemaSphere · doi:10.1097/hs9.0000000000000509 · Cited by 19
Nonclassic Inflammatory Bowel Disease in Young Infants
Chandrakasan, S., Venkateswaran, S., & Kugathasan, S. (2016) · Pediatric Clinics of North America · doi:10.1016/j.pcl.2016.08.010 · Cited by 17
Experimental gene therapies for the NCLs
Liu, W., Holthaus, S.-M. K., Herranz-Martín, S., Aristorena, M., Mole, S., Smith, A. J., Ali, R. R., & Rahim, A. A. (2020) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2020.165772 · Cited by 18
Hoffmann, D., Sens, J., Brennig, S., Brand, D., Philipp, F., Barbosa, P. V., Kuehle, J., Steinemann, D., Lenz, D., Buchegger, T., et al. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11030221 · Cited by 17
Self-citationCRISPR medicine for blood disorders: Progress and challenges in delivery
Gol, T. M., Ureña-Bailén, G., Hou, Y., Sinn, R., Antony, J. S., Handgretinger, R., & Mezger, M. (2023) · Frontiers in Genome Editing · doi:10.3389/fgeed.2022.1037290 · Cited by 16
Correcting inborn errors of immunity: From viral mediated gene addition to gene editing
Castiello, M. C., Ferrari, S., & VILLA, A. M. (2023) · Seminars in Immunology · doi:10.1016/j.smim.2023.101731 · Cited by 16
Roadmap for an early gene therapy for cystic fibrosis airway disease
Carlon, M. S., Vidović, D., & Birket, S. E. (2017) · Prenatal Diagnosis · doi:10.1002/pd.5164 · Cited by 16
Nuclease-free Adeno-Associated Virus-Mediated Il2rg Gene Editing in X-SCID Mice
Hiramoto, T., Li, L. B., Funk, S. E., Hirata, R. K., & Russell, D. W. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2018.02.028 · Cited by 16
Genetic Strategies for HIV Treatment and Prevention
Falkenhagen, A., & Joshi, S. (2018) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2018.09.018 · Cited by 16
Pluripotent stem cell based gene therapy for hematological diseases
Vanhee, S., & Vandekerckhove, B. (2015) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2015.08.022 · Cited by 16
A Curative DNA Code for Hematopoietic Defects
Porteus, M. H., Pavel-Dinu, M., & Pai, S. (2022) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2022.05.002 · Cited by 15
Self-citationGene Therapy for Inborn Errors of Immunity
Arlabosse, T., Booth, C., & Candotti, F. (2023) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2023.04.001 · Cited by 15
Kuppers, D. A., Linton, J., Ortiz‐Espinosa, S., McKenna, K. M., Rongvaux, A., & Paddison, P. J. (2023) · PLoS ONE · doi:10.1371/journal.pone.0287052 · Cited by 15
Advances and Challenges in the Development of Gene Therapy Medicinal Products for Rare Diseases
Bueren, J. A., & Auricchio, A. (2023) · Human Gene Therapy · doi:10.1089/hum.2023.152 · Cited by 17
Booth, C., Silva, J., & Veys, P. A. (2016) · Expert Review of Clinical Immunology · doi:10.1586/1744666x.2016.1150177 · Cited by 15
Advances of gene therapy for primary immunodeficiencies
Candotti, F. (2016) · F1000Research · doi:10.12688/f1000research.7512.1 · Cited by 15
Hähn, K., Pollmann, L., Nowak, J., Nguyen, A. H. H., Haake, K., Neehus, A., Waqas, S. F., Peßler, F., Baumann, U., Hetzel, M., et al. (2020) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2020.04.002 · Cited by 15
Murugesan, R., Karuppusamy, K. V., Marepally, S. K., & Thangavel, S. (2023) · Frontiers in Genome Editing · doi:10.3389/fgeed.2023.1148693 · Cited by 15
Thymocytes self‐renewal: a major hope or a major threat?
Peaudecerf, L., Krenn, G., Gonçalves, P., Vasseur, F., & Rocha, B. (2016) · Immunological Reviews · doi:10.1111/imr.12408 · Cited by 14
Integration Site Analysis in Gene Therapy Patients: Expectations and Reality
Biasco, L. (2017) · Human Gene Therapy · doi:10.1089/hum.2017.183 · Cited by 14
Multifunctional facets of retrovirus integrase
Grandgenett, D. P. (2015) · World Journal of Biological Chemistry · doi:10.4331/wjbc.v6.i3.83 · Cited by 14
Overview of the current status of gene therapy for primary immune deficiencies (PIDs)
Kuo, C. Y., & Kohn, D. B. (2020) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2020.05.024 · Cited by 15
Self-citationInnovative Cell-Based Therapies and Conditioning to Cure RAG Deficiency
VILLA, A. M., Capo, V., & Castiello, M. C. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.607926 · Cited by 14
Gene therapy's out-of-body experience
Scott, C. T., & DeFrancesco, L. (2016) · Nature Biotechnology · doi:10.1038/nbt.3592 · Cited by 14
Metadata
- Authors
- Hacein-Bey-Abina, S., Pai, S.-Y., Gaspar, H. B., Armant, M., Berry, C. C., Blanche, S., Bleesing, J., Blondeau, J., de Boer, H., Buckland, K. F., Caccavelli, L., Cros, G., De Oliveira, S., Fernández, K. S., Guo, D., Harris, C. E., Hopkins, G., Lehmann, L. E., Lim, A., London, W. B., van der Loo, J. C. M., Malani, N., Male, F., Malik, P., Marinovic, M. A., McNicol, A.-M., Moshous, D., Neven, B., Oleastro, M., Picard, C., Ritz, J., Rivat, C., Schambach, A., Shaw, K. L., Sherman, E. A., Silberstein, L. E., Six, E., Touzot, F., Tsytsykova, A., Xu-Bayford, J., Baum, C., Bushman, F. D., Fischer, A., Kohn, D. B., Filipovich, A. H., Notarangelo, L. D., Cavazzana, M., Williams, D. A., & Thrasher, A. J.
- Affiliations
- Boston Children's Hospital (US)
- Great Ormond Street Hospital (GB)
- Cincinnati Children's Hospital Medical Center (US)
- Inserm (FR)
- University College London (GB)
- Peoria campus of the University of Illinois System (US)
- Institut Pasteur (FR)
- University of Pennsylvania (US)
- Clinica Santa Maria (CL)
- Sorbonne Paris Cité (FR)
- Garrahan Hospital (AR)
- Medizinische Hochschule Hannover (DE)
- University of California, Los Angeles (US)
- Harvard University (US)
- ORCID
- Pai, Sung-Yun
- Gaspar, H. Bobby
- Armant, Myriam
- Bleesing, Jack
- Buckland, Karen F.
- Caccavelli, Laure
- Cros, Guilhem
- Fernández, Karen S.
- Harris, Chad E.
- Lehmann, Leslie E.
- London, Wendy B.
- Malani, Nirav
- Malik, Punam
- Moshous, Despina
- Ritz, Jerome
- Schambach, Axel
- Shaw, Kit L.
- Sherman, Eric A.
- Silberstein, Leslie E.
- Six, Emmanuelle
- Touzot, Fabien
- Tsytsykova, Alla
- Bushman, Frederic D.
- Fischer, Alain
- Kohn, Donald B.
- Notarangelo, Luigi D.
- Cavazzana, Marina
- Williams, David A.
- Thrasher, Adrian J.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2014-10-09
- Volume
- 371
- Issue
- 15
- Pages
- 1407-1417
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC4274995
- OpenAlex
- W2149628283
- Cited by
- 412
- References
- 46
- Citations by year
- 2026: 9 · 2025: 20 · 2024: 17 · 2023: 26 · 2022: 30 · 2021: 17 · 2020: 42 · 2019: 48 · 2018: 36 · 2017: 57 · 2016: 46 · 2015: 56 · 2014: 4
- FWCI
- 35.59
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- Wellcome Trust
- National Institute for Health and Care Research (NF-SI-0611-10001)
- National Heart, Lung, and Blood Institute (P01HL073104, HL073104, HHSN268201000009C)
- National Institute of Allergy and Infectious Diseases (U01AI087628, R01AI082020, P30AI045008, AI082020)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Life Sciences › Immunology and Microbiology › Immunology › Immunodeficiency and Autoimmune Disorders
- Health Sciences › Medicine › Oncology › CAR-T cell therapy research
- Keywords
- X-linked severe combined immunodeficiency, interleukin-2 receptor gamma chain, LMO2, MECOM, gene therapy, CD34+ hematopoietic stem cells, T cell reconstitution, adenovirus infection
- MeSH terms
- Animals, Genetic Vectors, Humans, Infant, Male, Mutation, T-Lymphocytes, Transduction, Genetic, Genetic Therapy, Gene Expression, Gammaretrovirus, DNA, Complementary, Antigens, CD34, Transgenes, Gene Silencing, Mice, Interleukin Receptor Common gamma Subunit, X-Linked Combined Immunodeficiency Diseases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
